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Abstract 
Background: The purpose of this study was to report: (1) the varying presentation of Paecilomyces ocular infections 
arising in Queensland; (2) the significance of immunosuppression as a primary determinant of disease; (3) the out-
comes of voriconazole use; and (4) the ongoing need for both surgical and medical management of this devastating 
fungal infection.
Methods: A retrospective case series of 21 culture proven individuals participated in this series and were identified 
via a review of the pathology reporting system utilized in the Queensland public health system. All culture proven 
individuals were subjected to a systematic chart review.
Results: The primary risk factor for Paecilomyces lilacinus infection is immunosuppression with 81.25 % of individu-
als being on some form of immunosuppression (i.e. systemic or topical). Of the cases 71.43 % had an intact epithelial 
surface at the time of diagnosis, and 76 % had no previous ocular history. The final visual outcomes were nine cases 
with HM vision or worse, three cases with 6/48–6/60 vision, three cases 6/12–6/24, and six cases with 6/12 vision or 
better. Despite voriconazole use rates of greater than 80 %, protracted and poor treatment outcomes continue to be 
commonplace.
Conclusions: Paecilomyces lilacinus is a filamentous fungus that has a predilection for immunosuppressed individu-
als. Despite in vitro and case reports demonstrating the effectiveness of voriconazole poor outcomes continue to be 
seen.
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Background
Paecilomyces is a filamentous saprophytic fungus that 
is found worldwide in soil, and as a contaminant in air 
and water. The fungus is typically resistant to multiple 
fungicidal agents, and was once considered primarily as 
a contaminate in culture due to its inherent resistance 
to available commercial sterile techniques [1, 2]. It is 
also found in fertilizers due to its bionematicidal effec-
tiveness against nematodes, which threaten commercial 
vegetation [3]. The species include: Paecilomyces lilaci-
nus, Paecilomyces variotti, Paecilomyces marquadnii and 
Paecilomyces javanicus, the former two being the most 
common cause of disease in humans [4–7]. Infection 
with Paecilomyces species is most common in the setting 
of immunosuppression [8–11], both topical and systemic, 
with rates of 76 % corticosteroid use in patients with ocu-
lar mycoses prior to diagnosis [12]. Cases of Paecilomy-
ces infection predominantly include ocular mycoses and 
mycoses of cutaneous or subcutaneous tissues [7]. Pae-
cilomyces has been shown to cause disease elsewhere in 
the body, but its predilection for the ocular surface and 
skin is thought to be due to a thermal intolerance of the 
fungus, with the optimum temperature for growth and 
sporulation, somewhere in the vicinity of 20–25 °C [13].
Ocular infection with Paecilomyces lilacinus has pre-
viously been reported to occur in the setting of chronic 
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keratopathy, after previous ocular surgery, following cor-
neal trauma, or with the use of soft contact lenses [12, 
14]. The literature with respect to previous ocular sur-
gery is somewhat skewed, with a large number of cases 
being reported in the early 1980s, occurring in the pres-
ence of contaminated intraocular lens implantation [15, 
16]. A few cases exist within the literature, demonstrat-
ing the occurrence of Paecilomyces lilacinus infection in 
the setting of an intact epithelial surface [17–22]. These 
cases initially presented with presumed immune-medi-
ated scleritis [21], nodular episcleritis [18], acute ante-
rior uveitis [19, 20], endophthalmitis [20], and corneal 
stromal or endothelial inflammation [17]. It has been 
postulated that an endogenous spread of the organism 
may be the underlying source of infection in these cases 
with an intact epithelium [17, 20, 22, 23]. However, few 
reports exist that identify Paecilomyces lilacinus within 
the systemic vasculature. Paecilomyces lilacinus has been 
identified in blood cultures, primarily in the presence of 
indwelling venous catheters, which subsequently became 
sterile after removal of the device [8, 24.]
A review of previous cases identified within Queens-
land, Australia was conducted to demonstrate: [1] the 
varying presentation of Paecilomyces ocular infections 
arising in Queensland; [2] the significance of immuno-
suppression as a primary determinant of disease; [3] the 
outcomes of voriconazole use; [4] the ongoing need for 
both surgical and medical management of this devas-
tating fungal infection; and [5] the need for protracted 
treatment.
Methods
A retrospective multi-centre case series was conducted of 
all culture proven cases of ocular Paecilomyces lilacinus 
occurring within Queensland Health between 2000 and 
2012. Ethics approval was gained from the Queensland 
Health Central Health and Medical Research Human 
Ethics Committee. Research adhered to the tenets of 
the Declaration of Helsinki. A search was undertaken of 
the electronic pathology system utilized by Queensland 
Health, namely Auslab and Auscare. A multi-centre study 
was conducted with cases coming from the two major 
referral centers within Queensland, The Princess Alex-
andra Hospital and The Royal Brisbane and Women’s 
Hospital. Search terms were Paecilomyces lilacinus and 
Paecilomyces species. Consent was obtained from par-
ticipants for treatment undertaken.
Within the database a total of 135 cases of Paecilomy-
ces lilacinus infection were identified. All non-ocular 
Paecilomyces infections were excluded from this study, 
providing a total of 21 cases of ocular Paecilomyces lilaci-
nus infection with samples coming from corneal tissue, 
corneal scrapes, aqueous and vitreous biopsy. Specimens 
were transported in sterile containers or in syringes in 
the case of fluid specimens. Specimens were inoculated 
on Sabouraud’s agar at 25  °C for up to 1 month. Identi-
fication was performed via phenotypic methods at local 
facilities. Some of these cases have been previously docu-
mented within the literature [18, 22]. Identified cases, 
were subjected to a systematic chart review. Information 
obtained during the review, included: name, record unit 
number, age, gender, resident location, specimen type, 
date of collection, date of presentation, initial diagnosis, 
actual diagnosis, risk factors, initial treatment and man-
agement prior to recognition of fungal infection, elapsed 
time before positive diagnosis, continued treatment both 
medical and surgical, outcome of management (i.e. res-
olution of infection, enucleation, phthisical eye), final 
visual acuity, duration of follow-up and previous ocular 
history.
Data obtained from the chart review were analysed, 
formulating simple descriptive statistics, utilising RCom-
mander Version 2.15.2 GUI 1.53.
Results
The case series consisted of 6 females and 15 males with a 
mean age of 52.48 years (SD = 17.51; range = 19.0–76.0) 
(Refer to Table  1—cases). The average distance from 
Brisbane Central Business District (CBD) was 340  km 
(SD =  578.94, range =  12.6–1755.0). The average dura-
tion of follow-up from the time of initial diagnosis to last 
review was 28.19 months (SD = 38.52; range = 1.0–144; 
median = 7 months). Sixteen (76 %) of the patients had 
no previous history of ocular disease or surgery, with 
Paecilomyces lilacinus infection being the initial pre-
senting problem for all these cases. Of the remaining 
five cases, two had a history of myopia and soft contact 
lens wear, two were bilateral pseudophakic, with one also 
having had a previous retinal detachment managed with 
scleral buckle, and one had a previous history of scleritis.
The primary risk factor for Paecilomyces infection was 
immunosuppression, with 50 % of patients being on sys-
temic immunosuppression (i.e. corticosteroids, cyclopho-
samide, azathioprine, sulfasalazine and methotrexate), 
31.25 % on topical immunosuppression (i.e. dexametha-
sone, prednisolone, fluoromethalone), 12.5  % having 
exposure to organic material and 12.5  % wearing soft 
contact lenses (one of the patients who wore soft contacts 
was also treated with topical steroids). Initial presenting 
diagnoses for patients included: 6 with scleritis/episcleri-
tis, 1 acute anterior uveitis, 2 with presumed toxoplasmo-
sis, 3 with foreign body induced keratitis, 2 with contact 
lens associated keratitis, 1 with herpetic interstitial kera-
titis, 1 with endogenous endophthalmitis, and 1 with an 
endothelial plaque with an uncertain diagnosis, and 3 
patients had no clear diagnosis at presentation.
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The time to positive diagnosis of Paecilomyces lilaci-
nus infection was on average 12.75  days (SD  =  9.51; 
range = 2–40). With final diagnoses for patients includ-
ing: 6 fungal endophthalmitis (28.57 %), 9 fungal kerati-
tis (42.86 %), 4 fungal keratoscleritis (19.05 %), 1 fungal 
keratitis leading to endophthalmitis (4.76 %), and 1 fun-
gal keratoscleritis leading to endophthalmitis (4.76 %). Of 
these cases, 15 had an intact epithelial surface (71.43 %) 
and 5 had a compromised epithelium (23.81  %). Medi-
cal management consisted of voriconazole, which 
was prescribed orally in 17 cases, followed by ampho-
tericin, which was given intravenously in 7 cases (Refer 
to Table  2—antifungal agent use). Some individuals 
required greater than 15 intravitreal injections of vori-
conazole in order to assist in resolution of the infection. 
One case of fungal keratitis, secondary to a foreign body, 
resolved without antifungal agents, solely with the use 
of ceftazidime and gentamicin. Of the 21 cases, 18 cases 
(85.7  %) required surgical intervention in order to help 
resolve the infection. Surgical intervention included, 8 
cases, which underwent penetrating keratoplasty and 9 
cases, which received a pars plana vitrectomy (PPV). Of 
those receiving a penetrating keratoplasty, 5 required at 
least a second penetrating keratoplasty, with one individ-
ual having a total of 4 grafts. Of the cases receiving PPV, 
4 cases of the group went onto have a second PPV (Refer 
to Table 3—surgical intervention). The final outcome for 
treatment, included 14 cases with resolution of infection 
(66.67 %), 4 cases with enucleation (19.05 %) and 3 cases 
with phthisis (14.29 %). The final visual outcomes were 9 
cases with HM vision or worse, 3 cases with 6/48–6/60 
vision, 3 cases 6/12–6/24, and 6 cases with 6/12 vision or 
better (Refer to Table 4—visual outcomes).
Discussion
Australia appears to have a high number of Paecilomyces 
lilacinus ocular infections in comparison to other parts 
of the world [7, 22]. Infection has typically been reported 
to arise in individuals with chronic ocular disease, con-
tact lens use or where the integrity of the eye has been 
disturbed (i.e. trauma, surgery) [12, 14]. In our study, 
we found that the majority of cases of infection arose in 
patients who had an intact epithelial surface and no pre-
vious ocular history, with 76 and 71.43  %, respectively. 
This is markedly different from one of the largest case 
series currently within the literature, which showed that 
only 5 of 17 individuals (29.4 %) had no apparent precipi-
tating factor [12], but in line with a recent published case 
series from Queensland, Australia which also showed the 
majority of patients also had no specific inciting cause 
[16, 22].
Previous case reports do exist in the literature high-
lighting the absence of epithelial breakdown and 
subsequent Paecilomyces lilacinus infection [17–23, 25], 
including a case of a suspected immune-mediated scle-
ritis and another of acute anterior uveitis [19, 21]. Other 
cases have also been reported, with a number included in 
this current review [18, 22]. The authors do not postulate 
as to the apparent mechanism of the infection, other than 
to state that it is most likely associated with systemic 
immunosuppression, previous history of scleritis, diabe-
tes or a previous biopsy that may have contributed to the 
evolution of the disease [21]. It has been suggested that 
Paecilomyces may be able to penetrate through an undis-
turbed epithelial surface or through micro-defects not 
visible to the naked eye [25]. Some researchers have also 
suggested that it may spread endogenously, even though 
few blood culture positive cases have been reported pre-
viously [17, 23]. Blood culture positive Paecilomyces typi-
cally occurs in association with intravascular prostheses 
[8, 24]. Furthermore, studies demonstrating the ability of 
Paecilomyces to actively infect animal and human cor-
neas have either involved inoculation directly into the 
stroma [26] or via scarification of the cornea [12]. We 
have been unable to identify a study that has attempted 
to demonstrate whether Paecilomyces can actively pen-
etrate an intact epithelium.
Immunosuppression is a significant determinant in the 
pathogenesis of paecilomyces infections. Previous reports 
highlighted the presence of immunosuppression in 76 % 
of cases of paecilomyces keratitis prior to diagnosis [12]. 
Murine models, with immunosuppressed mice (i.e. where 
their drinking water contained dexamethasone [10] or 
intraperitoneal cyclophosamide [27]), versus immuno-
competent mice, show an inability of paecilomyces to 
cause disease in the absence of immunosuppression. 












 Natamycin topical 8
 Itraconazole oral 3
 Terbinafine oral 2
 Posaconazole oral 1
 Fluconazole oral 1
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The mortality in immunosuppressed murine models is 
incredibly high with one hundred percent of mice suc-
cumbing to fungaemia 35–45 days post inoculation [10]. 
These laboratory models demonstrate the importance of 
immunosuppression as an important factor in the causal 
pathway of disease. In our study we found that 81.25  % 
of individuals were on some form of immunosuppression 
prior to diagnosis, either in the form of systemic or topi-
cal immunosuppression, further providing weight to the 
importance of immunosuppression as a risk factor.
Infection with Paecilomyces lilacinus, is notori-
ously resistant to available antifungal preparations. 
Clinical efficacy has been demonstrated for the use of 
voriconazole monotherapy [18, 26] and in combina-
tion with terbinafine [1, 5, 7, 28, 29]. In vitro evidence 
also exists for the efficacy for posaconazole and ravu-
conazole [7], and one of the patients in the series did 
receive oral posaconazole, due to deranged liver func-
tions as a result of oral voriconazole therapy. A recent 
case report also highlights the clinical efficacy of posa-
conazole in paecilomyces infection [30]. Voriconazole, 
a triazole antifungal, which inhibits fungal cytochrome 
P-450 mediated 14 α-lanosterol demethylation, a nec-
essary step in ergosterol synthesis. This leads to a loss 
of ergosterol, which is an essential component of the 
fungal cell wall. In-vitro minimum inhibitory concen-
trations (MICs) for voriconazole range from 0.12 to 
4.0  mg/L [7]. Numerous cases, within the literature 
have demonstrated the effective use of oral, topical, 
intravitreal and intracameral use of voriconazole for 
ocular Paecilomyces infection [5, 7, 12, 18, 29, 31–35]. 
Eighty percent of cases within our study were treated 
with voriconazole, at least with an oral preparation. 
Despite, the higher rate of voriconazole use within the 
study, 19 % of patients still went onto have an enuclea-
tion, which was higher than that previously reported, 
predominantly in the absence of voriconazole use (5 %) 
[12]. Furthermore, a significant number of patients in 
our series required combined surgical intervention in 
order to assist in resolution of the infection, with 85 % 
requiring either a penetrating keratoplasty, pars plana 
vitrectomy or enucleation. This is also greater than that 
previously demonstrated by Yuan and colleagues, but 
equivalent to their literature review of current cases 
in their article [12]. It is therefore suspected that even 
with the increased susceptibility of Paecilomyces lilaci-
nus to voriconazole treatment that combined surgical 
and medical management will remain the norm [22]. 
In addition, of the patient’s undergoing surgical inter-
vention, 66  % required repeated surgical intervention, 
in combination with protracted medical management 
with voriconazole. Individuals received a minimum of 
3  months oral voriconazole, with topical, intracameral 
or intravitreal voriconazole use dictated on a case-by-
case basis.
Conclusion
We believe that Paecilomyces lilacinus ocular infec-
tions require persistent and aggressive treatment, with 
combined surgical and medical management, which 
patients may not be willing to undertake. Outcomes 
of Paecilomyces ocular infection should be clearly 
discussed with patients inflicted with this devastating 
organism.
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6 6/28 PH 6/12 NPL
7 6/60 PH 6/36 HM
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